In addition, there were no significant differences in the percentages of naïve T cells, TCM, TEM, Treg, and Ts in CD4+T cells and naïve T cells, TCM, TEM, TEMRA, and Ts in CD8+T cells between the MS patients at pre-treatment and HCs (Fig 2A and 2B). The gene discussed is CD8A; the disease is myeloid sarcoma.